Selecta Biosciences (SELB)

Selecta Biosciences Stock Analysis & Ratings

SELB Stock Chart & Stats

Day’s Range$0.69 - $0.7479
52-Week Range$0.65 - $5.28
Previous Close$0.71
Average Volume (3M)1.16M
Market Cap$107.88M
P/E Ratio3.4
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)0.21



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Selecta Biosciences’s price range in the past 12 months?
Selecta Biosciences lowest stock price was $0.65 and its highest was $5.28 in the past 12 months.
    What is Selecta Biosciences’s market cap?
    Selecta Biosciences’s market cap is $107.88M.
      What is Selecta Biosciences’s price target?
      The average price target for Selecta Biosciences is $7.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $6.00. The average price target represents 931.52% Increase from the current price of $0.711.
        What do analysts say about Selecta Biosciences?
        Selecta Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Selecta Biosciences’s upcoming earnings report date?
          Selecta Biosciences’s upcoming earnings report date is Aug 11, 2022 which is in 77 days.
            How were Selecta Biosciences’s earnings last quarter?
            Selecta Biosciences released its earnings results on May 05, 2022. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.112 by $0.192.
              Is Selecta Biosciences overvalued?
              According to Wall Street analysts Selecta Biosciences’s price is currently Undervalued.
                Does Selecta Biosciences pay dividends?
                Selecta Biosciences does not currently pay dividends.
                What is Selecta Biosciences’s EPS estimate?
                Selecta Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Selecta Biosciences have?
                Selecta Biosciences has 151,810,000 shares outstanding.
                  What happened to Selecta Biosciences’s price movement after its last earnings report?
                  Selecta Biosciences reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.112. Following the earnings report the stock price went up 1.25%.
                    Which hedge fund is a major shareholder of Selecta Biosciences?
                    Among the largest hedge funds holding Selecta Biosciences’s share is Hussman Strategic Advisors Inc. It holds Selecta Biosciences’s shares valued at N/A.


                      Selecta Biosciences Stock Analysis

                      Smart Score
                      Price Target
                      ▲(931.52% Upside)
                      Strong Buy
                      The Selecta Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Selecta Biosciences

                      Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

                      Similar Stocks
                      Price & Change
                      Sanofi-Aventis Sa
                      Merck & Company
                      Genocea Biosciences
                      Johnson & Johnson

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis